Bimolane: In vitro inhibitor of human topoisomerase II

Cancer Letters

Volumn 120, Issue 2, 1997, Pages 135-140

  Frantz, Christopher E ^a   Smith, Heather ^a   Eades, Donald M ^b   Grosovsky, Andrew J ^a   Eastmond, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Bimolane; Chromosomal aberrations; Leukemia; Psoriasis; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; BIMOLANE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN;

ARTICLE; CHINA; CONTROLLED STUDY; DRUG DNA INTERACTION; DRUG MECHANISM; ENZYME INHIBITION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DNA, KINETOPLAST; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; RAZOXANE; SUBSTRATE SPECIFICITY;

EID: 0030693160     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00303-0     Document Type: Article

References (20)

1. Pedersen-Bjergaard J., Rowley J.D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780-2786.
2. Pedersen-Bjergaard J., Philip P., Larsen S.O.et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 7:1993;1975-1986.
3. Bhavnani M., Azzawi S.A., Yin J.A., Lucas G.S. Therapy-related acute promyelocytic leukaemia. Br. J. Haematol. 86:1994;231-232.
4. Zhang T., Chen Z., Lin C. Pharmacological studies on bimolane (AT-1727), a new antineoplastic agent. Acta Pharm. Sin. 15:1980;577-582.
5. Xu B., Noah P.W., Robert B., Skinner J., Bale G., Chesney T.M., Rosenberg E.W. Efficacy of bimolane in the Malassezia ovalis model of psoriasis. J. Dermatol. 18:1991;707-713.
6. Tanabe K., Ikegami Y., Ishida R., Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51:1991;4903-4908.
7. Onishi Y., Azuma Y., Kizaki H. An assay method for DNA topoisomerase activity based on separation of relaxed DNA from supercoiled DNA using high-performance liquid chromatography. Anal. Biochem. 210:1993;63-68.
8. Gorbsky G.J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (razoxane). Cancer Res. 54:1994;1042-1048.
9. Hochster H., Wasserheit C., Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr. Opin. Oncol. 7:1995;304-309.
10. Sehested M., Jensen P.B., Sorensen B.S., Holm B., Friche E., Demant E.J. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol. 46:1993;389-393.
11. Xue Y., Lu D., Guo Y., Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk. Res. 16:1992;1113-1123.
12. Li Y.S., Zhao Y.L., Jiang Q.P., Yang C.L. Specific chromosome changes and nonoccupational exposure to potentially carcinogenic agents in acute leukemia in China. Leuk. Res. 13:1989;367-376.
13. Caffrey E.A., Daker M.G., Horton J.J. Acute myeloid leukaemia after treatment with razoxane. Br. J. Dermatol. 113:1985;131-134.
14. Howard M.T., Lee M.P., Hsieh T.S., Griffith J.D. Drosophila topoisomerase II-DNA interactions are affected by DNA structure. J. Mol. Biol. 217:1991;53-62.
15. Prentki P., Karch F., Iida S., Meyer J. The plasmid cloning vector pBR325 contains a 482 base-pair-long inverted duplication. Gene. 14:1981;289-299.
16. Shapiro T.A. Kinetoplast DNA maxicircles: networks within networks. Proc. Natl. Acad. Sci. USA. 90:1993;7809-7813.
17. Froelich-Ammon S.J., Gale K.C., Osheroff N. Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. J. Biol. Chem. 269:1994;7719-7725.
18. Amir-Aslani A., Mauffret O., Bittoun P.et al. Hairpins in a DNA site for topoisomerase II studied by 1H- and 31P-NMR. Nucleic Acids Res. 23:1995;3850-3857.
19. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA. 91:1994;1781-1785.
20. Camerman N., Hempel A. Bimolane: structure determination indicates anticancer activity is attributable to ICRF-154. Science. 225:1984;1166-1167.